Erlocent 150 mg (Tablet)
Unit Price: ৳ 700.00 (1 x 10: ৳ 7,000.00)
Strip Price: ৳ 7,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Erlotinib |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- First-line treatment of patients with metastatic Non-Small Cell Lung cancer (NSCLC)
- Maintenance treatment of patients with locally advanced or metastatic NSCLC
- Treatment of locally advanced or metastatic NSCLC after failure of prior chemotherapy
- First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer
Description
- Chemical name: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine
- Reversibly inhibits the kinase activity of EGFR
- Prevents autophosphorylation of tyrosine residues associated with the receptor
- Higher binding affinity for EGFR exon 19 deletion or exon 21 (L858R) mutations
- Inhibition of other tyrosine kinase receptors not fully characterized
Dosage & Administration
- Recommended daily dose for NSCLC: 150 mg on an empty stomach
- Recommended daily dose for pancreatic cancer: 100 mg in combination with gemcitabine
- Reduce dosage with strong CYP3A4 inhibitors
- Increase dosage with CYP3A4 inducers
- Dose adjustment for concurrent cigarette smoking
Interaction
- Interaction with coumarin-derived anticoagulants
- Metabolized predominantly by CYP3A4
- Co-treatment with potent CYP3A4 inhibitor ketoconazole increased AUC
- Pre-treatment with CYP3A4 inducer Rifampicin decreased AUC
- Co-administration with drugs affecting gastric pH
Side Effects
- Common adverse reactions: rash, diarrhea, anorexia, fatigue, etc.
- Serious adverse reactions including Interstitial Lung Disease, Renal Failure, Hepatotoxicity, etc.
Pregnancy & Lactation
- Pregnancy category D
- Potential fetal harm
- Unknown presence in human milk
Precautions & Warnings
- Occurrence of Interstitial Lung Disease (ILD)
- Monitor renal function and electrolytes
- Monitor and withhold for severe or worsening liver tests
- Discontinue for gastrointestinal perforations or bullous skin disorders
- Increased risk of Myocardial infarction (MI)/ischemia
Use in Special Populations
- Safety and effectiveness in pediatric patients not established
- No overall differences in safety or efficacy observed in geriatric use
Overdose Effects
- Tolerability of single and repeated doses
- Unacceptable incidence of severe adverse reactions above recommended dose
- Symptomatic treatment for suspected overdose
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store at a temperature not exceeding 30°C
- Dry place, protect from light and moisture